Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All chlorhexidine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchChlorhexidineChlorhexidine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Use of chlorhexidine to eradicate oropharyngeal SARS‐CoV‐2 in COVID‐19 patients

Huang et al., Journal of Medical Virology, doi:10.1002/jmv.26954
Apr 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Viral clearance, spray and.. 85% Improvement Relative Risk Viral clearance, rinse only 60% Chlorhexidine  Huang et al.  LATE TREATMENT  RCT Is late treatment with chlorhexidine beneficial for COVID-19? RCT 173 patients in the USA (May - December 2020) Improved viral clearance with chlorhexidine (p<0.000001) c19early.org Huang et al., J. Medical Virology, Apr 2021 Favorschlorhexidine Favorscontrol 0 0.5 1 1.5 2+
45th treatment shown to reduce risk in January 2024
 
*, now with p = 0.00000000062 from 3 studies.
Lower risk for progression, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 81 treatments. c19early.org
RCT 294 hospitalized patients in the USA, showing faster oropharyngeal viral clearance with chlorhexidine. Results were better with a combination of oropharyngeal rinse and posterior oropharyngeal spray compared with the rinse alone.
Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects (early treatment may be more beneficial).
risk of no viral clearance, 85.1% lower, RR 0.15, p < 0.001, treatment 13 of 93 (14.0%), control 75 of 80 (93.8%), NNT 1.3, oropharyngeal rinse and spray, day 4.
risk of no viral clearance, 59.9% lower, RR 0.40, p < 0.001, treatment 25 of 66 (37.9%), control 52 of 55 (94.5%), NNT 1.8, oropharyngeal rinse only, day 4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Huang et al., 30 Apr 2021, Randomized Controlled Trial, USA, peer-reviewed, median age 62.0, 2 authors, study period 20 May, 2020 - 15 December, 2020. Contact: drjhuang@gmail.com.
This PaperChlorhexidineAll
Use of chlorhexidine to eradicate oropharyngeal SARS‐CoV‐2 in COVID‐19 patients
Y Hanna Huang, MD Jong T Huang
Journal of Medical Virology, doi:10.1002/jmv.26954
As public distribution of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is underway, prevention of coronavirus disease 2019 (COVID-19) relies on minimizing spread. In this study, chlorhexidine gluconate was investigated as a topical antimicrobial agent against SARS-CoV-2. This was a randomized, prospective cohort study using chlorhexidine as an oral rinse and posterior oropharyngeal spray in hospitalized COVID-19 patients. The primary outcome was presence or absence of laboratory-confirmed SARS-CoV-2 in the oral and oropharyngeal cavities after 4 days of chlorhexidine use and standard of care (study group) or standard of care only (control group). SARS-CoV-2 was eliminated from the oropharynx in 62.1% of patients who used chlorhexidine as an oral rinse, versus 5.5% of the control group patients. Among patients who used a combination of oral rinse and oropharyngeal spray, 86.0% eliminated oropharyngeal SARS-CoV-2, versus 6.3% of control patients. Chlorhexidine is a simple and safe addition to current COVID-19 prevention guidelines and may play a significant role in reducing disease spread.
CONFLICT OF INTERESTS The authors declare that there are no conflict of interests.
References
Anderson, Podgorny, Berríos-Torres, Strategies to prevent surgical site infections in acute care hospitals: 2014 update, Infect Control Hosp Epidemiol
Carrouel, Gonçalves, Conte, Antiviral activity of reagents in mouth rinses against SARS-CoV-2, J Dent Res, doi:10.1177/0022034520967933
Denton, Chlorhexidine, Disinfection, Sterilization and Preservation
Dhand, Li, Coughs and sneezes: their role in transmission of respiratory viral infections, including SARS-CoV-2, Am J Respir Crit Care Med
Firestone, Lorentz, Wang, First identified cases of SARS-CoV-2 variant B.1.1.7 in Minnesota -December 2020-January 2021, Morb Mortal Wkly Rep
Houston, Hougland, Anderson, Larocco, Kennedy et al., Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery, Am J Crit Care
Jones, Chlorhexidine: is it still the gold standard?, Periodontol
Khokhar, Roy, Purohit, Goyal, Setia, Viricidal treatments for prevention of coronavirus infection, Pathog Glob Health
Liu, Yan, Wan, Viral dynamics in mild and severe cases of COVID-19, Lancet Infect Dis
Meyers, Robison, Milici, Lowering the transmission and spread of human coronavirus, J Med Virol
Yoon, Yoon, Song, Clinical significance of a high SARS-CoV-2 viral load in the saliva, J Korean Med Sci
{ 'indexed': { 'date-parts': [[2021, 12, 22]], 'date-time': '2021-12-22T11:04:50Z', 'timestamp': 1640171090896}, 'reference-count': 13, 'publisher': 'Wiley', 'issue': '7', 'license': [ { 'start': { 'date-parts': [[2021, 4, 1]], 'date-time': '2021-04-01T00:00:00Z', 'timestamp': 1617235200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}, { 'start': { 'date-parts': [[2021, 4, 1]], 'date-time': '2021-04-01T00:00:00Z', 'timestamp': 1617235200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'http://doi.wiley.com/10.1002/tdm_license_1.1'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'short-container-title': ['J Med Virol'], 'published-print': {'date-parts': [[2021, 7]]}, 'DOI': '10.1002/jmv.26954', 'type': 'journal-article', 'created': {'date-parts': [[2021, 3, 23]], 'date-time': '2021-03-23T10:02:21Z', 'timestamp': 1616493741000}, 'page': '4370-4373', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 7, 'title': ['Use of chlorhexidine to eradicate oropharyngeal SARS‐CoV‐2 in COVID‐19 patients'], 'prefix': '10.1002', 'volume': '93', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-7949-5872', 'authenticated-orcid': False, 'given': 'Y. Hanna', 'family': 'Huang', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Medicine, Keck School of Medicine University of ' 'Southern California Los Angeles California USA'}]}, { 'given': 'Jong T.', 'family': 'Huang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Infectious Diseases Good Samaritan Hospital Los ' 'Angeles California USA'}]}], 'member': '311', 'published-online': {'date-parts': [[2021, 4]]}, 'reference': [ { 'key': 'e_1_2_8_2_1', 'unstructured': 'World Health Organization. Weekly Epidemiological Update – 2 March ' '2021.https://www.who.int/publications/m/item/weekly-epidemiological-update---2-march-2021. ' 'Accessed March 8 2021.'}, { 'key': 'e_1_2_8_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/20477724.2020.1807177'}, { 'key': 'e_1_2_8_4_1', 'unstructured': 'CDC. Coronavirus Disease 2019 (COVID‐19): How to Protect Yourself and ' 'Others. Atlanta GA: US Department of Health and Human Services CDC; ' '2020.'}, {'key': 'e_1_2_8_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/0022034520967933'}, {'key': 'e_1_2_8_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.26514'}, {'key': 'e_1_2_8_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1086/676022'}, { 'key': 'e_1_2_8_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1600-0757.1997.tb00105.x'}, {'key': 'e_1_2_8_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4037/ajcc2002.11.6.567'}, { 'key': 'e_1_2_8_10_1', 'first-page': '274', 'volume-title': 'Disinfection, Sterilization and Preservation', 'author': 'Denton GW', 'year': '1991'}, {'key': 'e_1_2_8_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3346/jkms.2020.35.e195'}, { 'key': 'e_1_2_8_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30232-2'}, {'key': 'e_1_2_8_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1164/rccm.202004-1263PP'}, {'key': 'e_1_2_8_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.15585/mmwr.mm7008e1'}], 'container-title': ['Journal of Medical Virology'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26954', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.26954', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26954', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 6, 15]], 'date-time': '2021-06-15T06:23:39Z', 'timestamp': 1623738219000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 4]]}, 'references-count': 13, 'journal-issue': {'issue': '7', 'published-print': {'date-parts': [[2021, 7]]}}, 'alternative-id': ['10.1002/jmv.26954'], 'URL': 'http://dx.doi.org/10.1002/jmv.26954', 'archive': ['Portico'], 'relation': {}, 'ISSN': ['0146-6615', '1096-9071'], 'issn-type': [{'value': '0146-6615', 'type': 'print'}, {'value': '1096-9071', 'type': 'electronic'}], 'subject': ['Infectious Diseases', 'Virology'], 'published': {'date-parts': [[2021, 4]]}, 'assertion': [ { 'value': '2020-12-25', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2021-03-17', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2021-04-01', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit